Jiangsu Bioperfectus Technologies Co Ltd (688399) - Total Liabilities

Latest as of September 2025: CN¥681.04 Million CNY ≈ $99.66 Million USD

Based on the latest financial reports, Jiangsu Bioperfectus Technologies Co Ltd (688399) has total liabilities worth CN¥681.04 Million CNY (≈ $99.66 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Jiangsu Bioperfectus Technologies Co Ltd (688399) cash flow conversion to assess how effectively this company generates cash.

Jiangsu Bioperfectus Technologies Co Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Jiangsu Bioperfectus Technologies Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 688399 financial resilience to evaluate the company's liquid asset resilience ratio.

Jiangsu Bioperfectus Technologies Co Ltd Competitors by Total Liabilities

The table below lists competitors of Jiangsu Bioperfectus Technologies Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Burelle SA
PA:BUR
France €5.89 Billion
Akasha Wira International Tbk
JK:ADES
Indonesia Rp516.28 Billion
Winner Information Technology Co Inc
SHE:300609
China CN¥220.83 Million
Eton Pharmaceuticals Inc
NASDAQ:ETON
USA $65.96 Million
Samsung Electro Mechanics Pref
KO:009155
Korea ₩4.80 Trillion
Elec-Tech International Co Ltd
SHE:002005
China CN¥770.56 Million
Chahua Modern Housewares Co Ltd
SHG:603615
China CN¥523.02 Million
Beijing Jiaxun Feihong Electrical Co Ltd
SHE:300213
China CN¥876.89 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Jiangsu Bioperfectus Technologies Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688399 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.32 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.23 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.19 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Jiangsu Bioperfectus Technologies Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Jiangsu Bioperfectus Technologies Co Ltd (2016–2024)

The table below shows the annual total liabilities of Jiangsu Bioperfectus Technologies Co Ltd from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥489.32 Million
≈ $71.60 Million
-2.39%
2023-12-31 CN¥501.31 Million
≈ $73.36 Million
-54.95%
2022-12-31 CN¥1.11 Billion
≈ $162.84 Million
+15.57%
2021-12-31 CN¥962.89 Million
≈ $140.90 Million
+57.03%
2020-12-31 CN¥613.18 Million
≈ $89.73 Million
+359.06%
2019-12-31 CN¥133.57 Million
≈ $19.55 Million
+86.91%
2018-12-31 CN¥71.46 Million
≈ $10.46 Million
+41.88%
2017-12-31 CN¥50.37 Million
≈ $7.37 Million
+47.74%
2016-12-31 CN¥34.09 Million
≈ $4.99 Million
--

About Jiangsu Bioperfectus Technologies Co Ltd

SHG:688399 China Biotechnology
Market Cap
$739.08 Million
CN¥5.05 Billion CNY
Market Cap Rank
#10619 Global
#3110 in China
Share Price
CN¥60.22
Change (1 day)
-2.48%
52-Week Range
CN¥45.89 - CN¥84.90
All Time High
CN¥419.88
About

Jiangsu Bioperfectus Technologies Co., Ltd., a molecular diagnostic company, engages in the research, development, production, and sale of in vitro diagnostic products in China. The company offers in vitro diagnostic reagents and supporting testing equipment, as well as in vitro testing services. It also provides HPV and cervical cancer testing services, respiratory infection detection solution, … Read more